Emcure Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• Emcure Pharmaceuticals Ltd reported a 8.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.5%.
• Its expenses for the quarter were up by 6.7% QoQ and 9.5% YoY.
• The net profit increased 17.0% QoQ and increased 24.7% YoY.
• The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 12.85 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Emcure Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and marketing of pharmaceutical products. The company is known for its broad range of offerings, including prescription drugs, over-the-counter medications, and biotechnology products. Emcure has a significant presence in both domestic and international markets, focusing on providing high-quality, affordable healthcare solutions. The company is dedicated to innovation and has a robust pipeline of pharmaceutical products aimed at addressing various therapeutic areas. As of the latest update, there are no specific recent major developments available for Emcure Pharmaceuticals Ltd.

Revenue

In the second quarter of the fiscal year 2026, Emcure Pharmaceuticals Ltd reported a total income of ₹2,272.94 crores. This figure represents an 8.0% increase from the first quarter of the same fiscal year, which had a total income of ₹2,104.23 crores. When compared to the second quarter of the previous fiscal year (Q2FY25), where the total income was ₹2,037.64 crores, there is an 11.5% year-over-year growth. This upward trend in revenue reflects the company's ongoing efforts to expand its market reach and enhance its sales capabilities.

Profitability

During the second quarter of FY26, Emcure Pharmaceuticals Ltd achieved a profit before tax of ₹341.42 crores, marking a 17.4% increase from the previous quarter's figure of ₹290.76 crores. Compared to the same quarter in the previous year (Q2FY25), where the profit before tax was ₹273.41 crores, there is a notable 24.9% increase. The company's profit after tax for this quarter stood at ₹251.37 crores, up by 17.0% quarter-over-quarter and 24.7% year-over-year. This improvement in profitability demonstrates the company's effective cost management and operational efficiency. The tax expense for the quarter was ₹90.05 crores, reflecting an 18.5% rise compared to the previous quarter and a 25.3% increase from the same period last year.

Operating Metrics

The earnings per share (EPS) for Emcure Pharmaceuticals Ltd in Q2FY26 was ₹12.85, compared to ₹10.92 in Q1FY26, showing a 17.7% quarter-over-quarter growth. Year-over-year, the EPS increased by 24.4% from ₹10.33 in Q2FY25. Total expenses for the quarter were ₹1,931.52 crores, up by 6.7% from ₹1,809.98 crores in the preceding quarter and by 9.5% from ₹1,764.23 crores in the same quarter of the previous year. These metrics highlight the company's operational growth and its ability to effectively manage expenses amidst increasing revenues.